EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Newborn screening for Duchenne muscular dystrophy: the perspectives of stakeholders

Charli Ji, Didu S Kariyawasam, Hugo Sampaio, Michelle Lorentzos, Kristi J Jones, Michelle A Farrar

The Lancet Regional Health - Western Pacific · 2024-04 · 45 · 101049

DOI: 10.1016/j.lanwpc.2024.101049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Regional Health - Western Pacific, 2024-04. Verfasst von Charli Ji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Sydney Children's Hospital Network, Sydney, New South Wales, Australia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The rapidly evolving clinical landscape of Duchenne muscular dystrophy (DMD) is driving innovative approaches for early diagnosis through genomic newborn bloodspot screening (NBS). However, the potential impact of these programs on families and healthcare systems remains unexplored. This study assessed the perceived benefits, harms, barriers, and enablers for DMD NBS amongst primary caregivers of children with DMD and healthcare professionals (HCPs).

Methods

This Australian multi-centre cross-sectional study used a mixed-methods convergent methodology. Participants completed a codeveloped questionnaire and their perceptions on the utility, model of care, and processes of DMD NBS were thematically analysed.

Findings

Participants included 50 caregivers and 26 HCPs (68.5% and 53.1% response rate respectively). Most caregivers (40/50, 80%) perceived net benefits of DMD NBS and highlighted an early diagnosis as actionable knowledge, even with the current paucity of disease modifying therapies. This knowledge was valued to enable access to multidisciplinary supportive care (29/50, 58%), clinical trials (27/50, 54%), psychological support (28/50, 56%), inform reproductive planning (27/50, 54%), and facilitate financial planning based on the future needs of their child (27/50, 54%). Whilst HCPs acknowledged these opportunities, only 16/26 (61.5%) believed there were definite net benefits, with notable concerns over the psychological harms of diagnostic knowledge without a recourse to disease modifying therapeutic intervention early in life.

Interpretation

Caregivers and HCPs perceived a range of potential benefits of DMD NBS. Health system readiness will be founded on developing an integrated model of care that not only supports the psychosocial and information needs of families receiving a newborn diagnosis of DMD, but also provides care and clinical surveillance for individuals for whom a diagnosis may remain uncertain. Funding: Medical Research Futures fund (GNT2017165, MRF2015965).

Schlagwörter

Stichwörter der Autor:innen

CaregiverDuchenne muscular dystrophyNewborn screeningPerspectivesProvider

Autor:innen und Institutionen

  • Department of Neurology, Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
  • Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, New South Wales, Australia.
  • The T.Y. Nelson Department of Neurology and Neurosurgery, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Discipline of Paediatrics, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Clinical Genetics, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Discipline of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Ji, C., Kariyawasam, D. S., Sampaio, H., Lorentzos, M., Jones, K. J., & Farrar, M. A. (2024). Newborn screening for Duchenne muscular dystrophy: the perspectives of stakeholders. The Lancet Regional Health - Western Pacific, 45, 101049. https://doi.org/10.1016/j.lanwpc.2024.101049

Vancouver

Ji C, Kariyawasam DS, Sampaio H, Lorentzos M, Jones KJ, Farrar MA. Newborn screening for Duchenne muscular dystrophy: the perspectives of stakeholders. The Lancet Regional Health - Western Pacific. 2024;45:101049. doi:10.1016/j.lanwpc.2024.101049

BibTeX
@article{Ji2024,
  author = {Ji, Charli and Kariyawasam, Didu S and Sampaio, Hugo and Lorentzos, Michelle and Jones, Kristi J and Farrar, Michelle A},
  title = {Newborn screening for Duchenne muscular dystrophy: the perspectives of stakeholders},
  journal = {The Lancet Regional Health - Western Pacific},
  year = {2024},
  volume = {45},
  pages = {101049},
  doi = {10.1016/j.lanwpc.2024.101049}
}
Kostenlos starten →